BioReference Lab's GenPath division will notify treating oncologists when a genomic alteration is detected that matches an NCI-MATCH treatment arm.
Seventeen organizations don't support the Diagnostic Accuracy and Innovation Act as written and would like lawmakers to advance a CLIA-centric framework.
The partners are planning to conduct meta-analyses of shared exome datasets from patients with inherited neurological disorders.
Opko subsidiary Bio-Reference Laboratories is retiring GeneTests.org next month given the availability of the NIH-backed Genetic Testing Registry.
The alliance will combine the two firms' technologies and know-how to provide doctors with insights into patients' health status.
Under today's deal, all of UC Health's medical centers will work with GeneDx and have access to more than 400 of the firm's tests for rare hereditary disorders.
Diaceutics will use the data to help its pharmaceutical industry clients speed their rollouts of new cancer drugs.
Going forward, Natera said it will market its Panorama NIPT assay and carrier screening test Horizon directly to physicians.
Around 16,000 4Kscore prostate cancer tests were performed in Q3, which is a 365 percent increase over Q3 2015.
Experts said that the EMR is a crucial channel for aggregating clinical insights from multiple sources, but plenty of work is needed to achieve broader adoption.
A University of California, Los Angeles-led team has found turning off the CCR5 gene could improve recovery after a stroke, according to Scientific American.
South Dakota lawmakers are to weigh a bill aimed at teaching the strengths and weaknesses of scientific concepts, the Associated Press and KEVN-Black Hills Fox report.
In Science this week: the synthetic genetic system hachimoji, and more.
Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.